Pharmacy Services

Albany, NY, United States

Pharmacy Services

Albany, NY, United States

Time filter

Source Type

News Article | February 15, 2017
Site: www.prweb.com

The Excelera network consists of point-of-care specialty pharmacies owned by health systems and academic medical centers. The network provides members nationally scaled infrastructure and support to help them develop best practices and gain access to limited-distribution drugs and biologics and restrictive payer agreements so members can provide continuity of care for their patients with complex and chronic conditions requiring specialty drugs and biologics. The network also serves as a national platform for collaboration to optimize outpatient specialty drug therapy for population health. “Partnering with Excelera to develop our specialty pharmacy operations is a win for our most complex patients, who will receive comprehensive specialty services more expeditiously than if we were to go it alone,” said Kyle Townsend, Director of Pharmacy Services Billings Clinic. “Plus, we get the benefit of access and insight from thought leaders across the country who are grappling with the same challenges of providing high-quality care at a reduced cost with the best possible patient outcomes.” “Billings Clinic is a physician-led, integrated multispecialty group practice that exemplifies the highest national standards in hospital care and management,” said Jim Fox, Chief Executive Officer of the Excelera network. “We are pleased to welcome Billings Clinic into our national network and look forward to building an enduring relationship.” Specialty pharmaceuticals are expensive drugs that require special handing and administration and are often used to treat the most ill and clinically complex patients. The Excelera organization will partner with Billings Clinic to develop key specialty pharmacy capabilities including training, operations, data aggregation, reporting for drug manufacturers and payers, revenue cycle management and pharmacy business office. ExceleraRx Corp. supports the Excelera® Specialty Pharmacy Network, a national network of specialty pharmacies based at health systems and academic medical centers, enabling member organizations to gain access to limited distribution drugs and restricted payer agreements. The Excelera network provides national-scale efficiency and collaboration to improve quality and value of outpatient specialty drug therapy for population health outcomes. Excelera’s mission is to “provide tools, technology and best practices around high-performing specialty pharmacy capabilities to network members, so that they can provide integrated, coordinated care to complex patients at the point-of-care leading to improved health outcomes and decreased healthcare costs.” For a current list of Excelera specialty pharmacy network members, or for more information about becoming a member of the Excelera national specialty pharmacy network, visit excelerarx.com or follow us on LinkedIn. Billings Clinic is Montana’s largest health system serving Montana, Wyoming and the western Dakotas. A not-for-profit organization led by a physician CEO, Billings Clinic is governed by a board of community members, nurses and physicians. At its core, Billings Clinic is a physician-led, integrated multispecialty group practice with a 304-bed hospital and Level II trauma center. Billings Clinic has more than 4,100 employees, including 450 physicians and advanced practitioners offering more than 50 specialties. More information can be found at http://www.billingsclinic.com


News Article | May 9, 2017
Site: www.businesswire.com

ORLANDO, Fla.--(BUSINESS WIRE)--Guardian Pharmacy Services LLC, one of the nation’s largest long-term care (LTC) pharmacy companies, today announced the opening of Guardian Pharmacy of Orlando. The new location marks Guardian’s seventh pharmacy in Florida and enhances the group’s ability to provide quality products and services to residents in assisted living, skilled nursing, and other long-term care communities across the entire state. Guardian Pharmacy of Orlando was founded after completing the purchase of Central Care Pharmacy. The new pharmacy will be led by industry veterans Alan Obringer, RPh, who will serve as president of the pharmacy, and Jill Daly, director of sales and marketing. Sridhar Nadimpalli, RPh, the previous owner of Central Care Pharmacy, will stay on board with Guardian as the director of operations. “Guardian has a reputation for providing the highest level of customer service and personalized support focused on resident well-being, which was extremely important to me in a pharmacy partner,” said Sridhar Nadimpalli, founder of Central Care Pharmacy. “I look forward to working with Alan, Jill and their team and know they will take the pharmacy to new heights and continue providing excellent care to our local communities.” In addition to Nadimpalli, three former Central Care employees will also join the Guardian Orlando team, increasing its employee count to 15 with plans to hire additional staff by year end. Currently, Guardian Orlando serves more than 500 residents but expects that number to triple as early as this July. “Since opening Guardian Orlando, we have continued to identify new ways to provide superior care for our residents,” said Alan Obringer, president of Guardian Pharmacy of Orlando. “In order to make the most out of every patient interaction, we have installed innovative technology including a Parata multi-dispensing system and are currently building a new space in the pharmacy to house and distribute compound sterile preparations. With these new offerings and the expertise of our staff, we are well- positioned to provide market leading service to the Orlando LTC market.” As new members of the Guardian family, the Orlando pharmacy will benefit from the company’s industry unique Local-Autonomy business model, in which Obringer and his team will focus on customer service to meet the specialized needs of its residents, while Guardian’s corporate team assists with the time consuming day-to-day business operations including payroll, HR, IT and more. “Setting up a new location in Orlando was an easy decision for us. It not only allows Guardian to better serve this attractive market but to also fully service the entire Florida LTC community,” added Kendall Forbes, EVP of sales and operations of Guardian Pharmacy Services. “We are confident Alan and his team will experience great growth and success in the market and will continue to carry on the Guardian reputation for excellence.” Guardian Pharmacy of Orlando is one of 29 pharmacies in the Guardian family that together serve 20 states and more than 89,000 residents, making it one of the nation’s largest long-term care pharmacy companies. For more information, visit guardianpharmacyflorida.com or guardianpharmacy.net. Guardian Pharmacy Services, headquartered in Atlanta, Ga., is one of the nation’s largest long-term care pharmacy companies. Guardian’s pharmacies provide outstanding client service to long-term care facilities including assisted living, skilled nursing and others. Founded in 2004, Guardian is best known for its unique Local-Autonomy business model, where pharmacy operators participate in local ownership and benefit from Guardian’s experience in high-growth, specialty pharmacies. www.guardianpharmacy.net.


News Article | May 11, 2017
Site: www.businesswire.com

PARSIPPANY, N.J.--(BUSINESS WIRE)--The Personalized Medicine (PM) Connective announced the achievement of several milestones today. Jeff Waldron, Executive Director of the PM Connective, highlighted the developments, which include creating a new leadership panel, securing a second round of funding, and increasing brand awareness. At the PM Connective’s Strategic Task Force Meeting in March, Waldron announced the formation of an Advisory Panel for the PM Connective to be comprised of senior ambassadors to help open doors and represent the organization externally. Peter Keeling, CEO of Diaceutics and Chairman of the PM Connective’s Board said, “We are pleased to announce that Peter Kapitein has agreed to serve as Chairman of our new Advisory Panel. Peter is the inspirational founder and leader of Inspire2Live, a Netherlands–based patient advocacy organization working to inspire patients, clinicians, and researchers to work together to get cancer under control by 2021 and to help people lead healthy lives in harmony with cancer. He will be recruiting 3-4 additional visionaries to join him on the Advisory Panel. Kapitein described his passion that “personalized medicine has the capacity to transform healthcare, but we must always maintain the patient-centric focus . . . because our true success will be measured in health outcomes and the quality of life for patients and their families.” Concurrent with the formation of the Advisory Panel, Waldron also announced that the PM Connective just received funding from Cardinal Health. Cardinal Health, a global, integrated healthcare services and products company, provides customized solutions for hospital systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide, and ranks among the top 25 on the Fortune 500. They join Diaceutics as the inaugural funders of the PM Connective. Tiffany Olson, President of Nuclear Pharmacy Services (NPS) at Cardinal Health and a PM Connective Task Force member, sponsored the funding. She explained, “Personalized Medicine has been talked about for decades, but it is unlikely to deliver on its original promise without rethinking how to deliver radical change. Therefore, the PM Connective’s disease-specific approach, combined with bringing together the silos of healthcare, will model that radical change, clinically and economically.” Following on the heels of these two milestones, the just released March/April issue of the Journal of Precision Medicine features a pair of articles on the PM Connective . . . one introducing the background and mission and the second summarizing results from the initial workshops. Waldron emphasized, “These two articles in the Journal of PM highlight the progress the PM Connective has made through our first two melanoma workshops hosted by the Rutgers Cancer Institute. These daylong sessions featured collaborators from the major healthcare silos that collectively generated 19 key issues and melanoma interventions to be quantified in our proprietary valuation framework. We will define the benefits in both health outcomes and economic terms not only across all of the silos in aggregate . . . but also for each individual silo to ensure that our model for personalized medicine doesn’t disadvantage any stakeholder.” This culminates a partnership with the Journal of PM that began last August when Waldron co-led a Roundtable on Overcoming Obstacles to Personalized Medicine at the Journal’s Precision Medicine Leaders’ Summit in San Diego along with Katie Johansen Taber, VP of PM for the AMA. The PM Connective will be participating in this Summit again on August 21-24 in San Diego. Finally, in mid-February, the PM Connective attended the Melanoma Research Alliance Scientific Retreat in Washington . . . a premier melanoma gathering of key leaders from major academic, research, clinical, industry, and patient advocacy groups. At the pre-Retreat session for patient advocates and foundations, Jeff introduced the PM Connective and its unique mission. He explained “We are seeking to become integrators in personalized medicine starting with melanoma, which is highly curable if diagnosed and treated early. Our preliminary data shows prompt diagnosis and first-line treatment has the power to transform patient outcomes and dramatically lower healthcare costs as a result.” The PM Connective is a 501(c)(6) not-for-profit organization registered in New Jersey. Two hundred healthcare experts representing most major stakeholder groups conceived it in 2015. They convened in Dublin and set aside their competitive agendas to search for an answer to the question “how can we advance personalized medicine?” The consensus felt that disconnected stakeholders . . . each in their own silo . . . was restraining PM from achieving its potential. Thus, the PM Connective was launched as an unbiased facilitator to drive collaboration and integration across all healthcare industry silos. The founders felt it should be focused at the disease-specific level in order to produce a more implementable solution. After significant research, it was decided to begin with metastatic melanoma and to design a PM model with a corresponding valuation framework to prove the clinical and economic benefits of personalized healthcare.


News Article | May 22, 2017
Site: www.prweb.com

OSF Ventures, the corporate investment arm of OSF HealthCare, is part of a larger group investing in InsightRX, an early stage company in San Francisco that has developed software to individualize treatment based on a patient’s underlying biological and pharmacological characteristics. Greatpoint Ventures Innovation Fund acted as the lead investor in the round. Medicine is typically prescribed for the “average patient” based mainly on weight and age. InsightRX aims to change that by giving clinicians and pharmacists the tools they need to select the right drug and dose for the right patient. The company’s software platform leverages mathematical models, patient demographics, physiological characteristics, genomic data, drug concentrations and biomarkers to get a detailed understanding of a patient’s response to different treatment strategies. Its initial work has mostly focused on chemotherapy drugs for children and certain complex antibiotics. “InsightRX will allow pharmacists to efficiently and safely dose patients prescribed high risk drugs, leading to shortened hospitalization stays and improved outcomes,” said Jerry Storm, Senior Vice President of Pharmacy Services at OSF HealthCare. “As population health matures, this technology will allow OSF to target specific patients for gene testing and dose appropriately to decrease adverse reactions.” OSF Ventures was connected to InsightRX thanks to its partnership with Plug and Play, the world’s largest start-up platform headquartered in Silicon Valley that connects startups to corporations and invests in more than 100 companies a year. “We see the potential of InsightRX to revolutionize how drugs are administered to patients world-wide, leading to improved care and limiting side effects that can impact patients for the rest of their lives,” said Stan Lynall Vice President of Ventures Investments for OSF Ventures. “Our investment in this company also opens up opportunities to co-develop additional drug dosing modules for the purposes of serving our patients.” It’s been a little more than one year since OSF Ventures launched in 2016 to strategically invest in new technology and devices that can transform and improve health care. It’s invested in eight companies since its inception. OSF HealthCare, headquartered in Peoria, is owned and operated by The Sisters of the Third Order of St. Francis, and consists of more than 18,000 employees in 115 locations, including 11 hospitals throughout Illinois and Michigan. Its physician network employs more than 1,000 primary care, specialist physicians and advanced practice providers. More at http://www.osfhealthcare.org. OSF Ventures specializes in venture optimization, partnering financially and operationally in companies that improve patient outcomes and reduce costs to health care systems. OSF Ventures is a division of OSF HealthCare. More at http://www.osfventures.org. InsightRX, based in San Francisco, has developed a cloud-based platform for precision medicine and clinical analytics. The technology underlying the InsightRX platform incorporates the principles of quantitative pharmacology and machine learning to provide a detailed understanding of a patient’s response to treatment. More at http://www.insight-rx.com.


News Article | February 23, 2017
Site: co.newswire.com

Synergy Pharmacy Services proudly announces its achievement of PCAB accreditation, a service of Accreditation Commission of Health Care (ACHC), thus joining an elite group of pharmacies nationwide with this distinction. The accreditation demonstrates that Synergy Pharmacy Services meets the highest quality and safety standards in its profession. To earn PCAB Accreditation, Synergy Pharmacy Services had to complete an extensive application, document its written policies and provide an analysis of its quality procedures that was reviewed by the Pharmacy Compounding Accreditation Board and some of the leading figures in the field of compounding. Next, the pharmacy opened its doors for an extensive on-site inspection led by compounding experts. Only when these stringent evaluations were completed did the Pharmacy Compounding Accreditation Board officially grant Synergy Pharmacy Services the PCAB Seal of Accreditation and the right to use the designation “PCAB Accredited™ compounding pharmacy.” “We are honored by this accreditation. It confirms our dedication to protecting our patients by practicing safe, high-quality personalized solutions that address patient’s medical needs,” said Michael Palso, Synergy Pharmacy Services COO. “We believe this will only further strengthen the bonds of trust between our pharmacy, the patients, and the healthcare providers who rely on us for these specialized medications.” Compounding medications is an integral part of the practice of pharmacy and the demand for these customized medications increases every year. Compounded medications are prescriptions that are written by physicians, veterinarians, and other legally authorized prescribers and prepared for an individual patient by a specially trained pharmacist. The Pharmacy Compounding Accreditation Board is a not-for-profit corporation formed by eight national pharmacy organizations that recognized the need for a national standards organization for compounding pharmacy. Together, these leading organizations developed the policies and standards for the practice of compounding pharmacy, as well as the PCAB Accreditation criteria and processes. For more information on PCAB Accreditation, visit the PCAB Web site at www.pcab.org. Established in 2010, Synergy Pharmacy Services is an award-winning specialty pharmacy. With a focus on pain management, Synergy Pharmacy Services provides compounding, specialty drugs, and retail services to patients nationwide. In addition to the newly appointed PCAB accreditation, Synergy is a proud member of the International Academy of Compounding Pharmacists (IACP), National Association of Boards of Pharmacy, American College of Apothecaries (ACA), and Florida Pharmacy Association (FPA). For more information about Synergy Pharmacy Services, Inc, please visit www.synergyrx.com.


LONDON, UK / ACCESSWIRE / March 1, 2017 / Active Wall St. announces its post-earnings coverage on CVS Health Corp. (NYSE: CVS). The Company released its financial results for the fourth quarter fiscal 2017 (Q4 FY17) and full year 2017 (FY17) on February 09, 2017. The Drugstore chain and pharmacy benefits manager's earnings outperformed market expectations. Register with us now for your free membership at: One of CVS Health's competitors within the Health Care Plans space, Magellan Health, Inc. (NASDAQ: MGLN), reported its earnings for Q4 ended on December 31, 2016, on Friday, February 24, 2017. AWS will be initiating a research report on Magellan Health in the coming days. Today, AWS is promoting its earnings coverage on CVS; touching on MGLN. Get our free coverage by signing up to: CVS announced that net revenues for the three months ended December 31, 2016, increased 11.7% to $46.0 billion, up from $41.1 billion in Q4 2015. The Company's revenue numbers came in below market estimates of $46.51 billion. For the year ended December 31, 2016, CVS' net revenues increased 15.8% to $177.5 billion compared to $153.3 billion for FY15. CVS' net income for Q4 2016 was $1.71 billion, or $1.59 per share, compared to net income of $1.50 billion, or $1.34 per share, during Q4 2015. The Company benefited from a lower effective income tax rate in the reported quarter of 38.0% versus 38.9% in the prior year's same period. CVS' adjusted earnings per share for Q4 2016 was $1.71 compared to $1.53 for Q4 2015, and surpassed analysts' consensus of $1.67 per share. The Company's GAAP diluted EPS for year ended December 31, 2016 was $4.91 compared to $4.62 in the prior year. Net income for the year ended December 31, 2016, was $5.3 billion, an increase of $80 million, or 1.5%. CVS generated approximately $1.5 billion of free cash during the quarter and $8.1 billion for the full year 2016, which was above the high-end of its guidance range. In FY16, CVS returned $6.3 billion to shareholders through dividends and share repurchases. During Q4 2016, the Company repurchased 6.1 million shares for $461 million, or $75.20 per share. In FY16, CVS repurchased 48 million shares for $4.5 billion, or $96.78 per share. CVS's revenues in the Pharmacy Services segment increased 17.9% to $31.3 billion in Q4 2016, primarily driven by growth in pharmacy network and specialty pharmacy claims. Pharmacy network claims processed during the reported period, increased 23.9% to 294.3 million, compared to 237.4 million in the prior year. The increase in pharmacy network claim volume was primarily due to an increase in net new business. CVS' Mail choice claims processed during Q4 2016, increased 4.7% to 23.2 million compared to 22.2 million in the prior year. CVS' revenues in the Retail/LTC segment increased 4.7% to $20.8 billion in Q4 2016, largely driven by the addition of the pharmacies of Target Corporation, which were acquired in December 2015. Pharmacy same store prescription volumes rose 2.0% on a 30-day equivalent basis. Same store sales decreased 0.7% versus the prior year, with pharmacy same store sales up 0.2% and front store same store sales down 2.9%. Front store same store sales were negatively impacted by softer customer traffic and efforts to rationalize promotional strategies, partially offset by an increase in basket size. Pharmacy same store sales were negatively impacted for Q4 2016 by approximately 380 basis points due to recent generic introductions. CVS reported that for Q4 2016, the generic dispensing rate increased approximately 170 basis points to 85.4% in its Pharmacy Services segment and increased approximately 120 basis points to 85.2% in the Company's Retail/LTC segment compared to the prior year. For Q4 2016, CVS' consolidated operating profit increased $266 million. Operating profit for the reported quarter increased $242 million in the Pharmacy Services segment and decreased $53 million in the Retail/LTC segment. The Pharmacy Services segment operating profit included the favorable impact of a reversal of an accrual of $88 million in connection with a legal settlement. Corporate segment operating expenses decreased $92 million from the prior year primarily due to the $90 million legal charge in the prior year associated with a disputed 1999 legal settlement. For FY16, CVS' consolidated operating profit increased $884 million. Operating profit for the year had increased by $683 million in the Pharmacy Services segment and $151 million in the Retail/LTC segment. During Q4 2016, CVS opened 40 new retail stores and closed 25 retail stores. In addition, the Company relocated 16 retail stores. As of December 31, 2016, the Company operated 9,709 retail stores, including pharmacies in Target stores, in 49 states, the District of Columbia, Puerto Rico and Brazil. CVS intends to close approximately 70 retail stores during 2017 and expects to take a charge of approximately $225 million associated with the remaining lease obligations of such stores. The vast majority of the store closures are expected to occur in Q1 2017. In connection with such anticipated store closures, the Company recorded a $34 million asset impairment charge in Q4 2016. CVS expects to deliver GAAP diluted EPS of $5.02 to $5.18 and adjusted EPS of $5.77 to $5.93 for FY17. The Company expects to deliver GAAP diluted EPS of $0.82 to $0.88 and adjusted EPS of $1.07 to $1.13 in Q1 2017. The Company also confirmed its FY17 cash flow from operations guidance of $7.7 billion to $8.6 billion and free cash flow guidance of $6.0 billion to $6.4 billion. At the close of trading session on Tuesday, February 28, 2017, CVS Health's stock price slipped 1.02% to end the day at $80.58. A total volume of 7.27 million shares were exchanged during the session. The Company's share price has gained 9.46% in the past three months and 2.73% on YTD basis. The stock is trading at a PE ratio of 16.35 and has a dividend yield of 2.48%. Additionally, the stock currently has a market cap of $85.74 billion. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. LONDON, UK / ACCESSWIRE / March 1, 2017 / Active Wall St. announces its post-earnings coverage on CVS Health Corp. (NYSE: CVS). The Company released its financial results for the fourth quarter fiscal 2017 (Q4 FY17) and full year 2017 (FY17) on February 09, 2017. The Drugstore chain and pharmacy benefits manager's earnings outperformed market expectations. Register with us now for your free membership at: One of CVS Health's competitors within the Health Care Plans space, Magellan Health, Inc. (NASDAQ: MGLN), reported its earnings for Q4 ended on December 31, 2016, on Friday, February 24, 2017. AWS will be initiating a research report on Magellan Health in the coming days. Today, AWS is promoting its earnings coverage on CVS; touching on MGLN. Get our free coverage by signing up to: CVS announced that net revenues for the three months ended December 31, 2016, increased 11.7% to $46.0 billion, up from $41.1 billion in Q4 2015. The Company's revenue numbers came in below market estimates of $46.51 billion. For the year ended December 31, 2016, CVS' net revenues increased 15.8% to $177.5 billion compared to $153.3 billion for FY15. CVS' net income for Q4 2016 was $1.71 billion, or $1.59 per share, compared to net income of $1.50 billion, or $1.34 per share, during Q4 2015. The Company benefited from a lower effective income tax rate in the reported quarter of 38.0% versus 38.9% in the prior year's same period. CVS' adjusted earnings per share for Q4 2016 was $1.71 compared to $1.53 for Q4 2015, and surpassed analysts' consensus of $1.67 per share. The Company's GAAP diluted EPS for year ended December 31, 2016 was $4.91 compared to $4.62 in the prior year. Net income for the year ended December 31, 2016, was $5.3 billion, an increase of $80 million, or 1.5%. CVS generated approximately $1.5 billion of free cash during the quarter and $8.1 billion for the full year 2016, which was above the high-end of its guidance range. In FY16, CVS returned $6.3 billion to shareholders through dividends and share repurchases. During Q4 2016, the Company repurchased 6.1 million shares for $461 million, or $75.20 per share. In FY16, CVS repurchased 48 million shares for $4.5 billion, or $96.78 per share. CVS's revenues in the Pharmacy Services segment increased 17.9% to $31.3 billion in Q4 2016, primarily driven by growth in pharmacy network and specialty pharmacy claims. Pharmacy network claims processed during the reported period, increased 23.9% to 294.3 million, compared to 237.4 million in the prior year. The increase in pharmacy network claim volume was primarily due to an increase in net new business. CVS' Mail choice claims processed during Q4 2016, increased 4.7% to 23.2 million compared to 22.2 million in the prior year. CVS' revenues in the Retail/LTC segment increased 4.7% to $20.8 billion in Q4 2016, largely driven by the addition of the pharmacies of Target Corporation, which were acquired in December 2015. Pharmacy same store prescription volumes rose 2.0% on a 30-day equivalent basis. Same store sales decreased 0.7% versus the prior year, with pharmacy same store sales up 0.2% and front store same store sales down 2.9%. Front store same store sales were negatively impacted by softer customer traffic and efforts to rationalize promotional strategies, partially offset by an increase in basket size. Pharmacy same store sales were negatively impacted for Q4 2016 by approximately 380 basis points due to recent generic introductions. CVS reported that for Q4 2016, the generic dispensing rate increased approximately 170 basis points to 85.4% in its Pharmacy Services segment and increased approximately 120 basis points to 85.2% in the Company's Retail/LTC segment compared to the prior year. For Q4 2016, CVS' consolidated operating profit increased $266 million. Operating profit for the reported quarter increased $242 million in the Pharmacy Services segment and decreased $53 million in the Retail/LTC segment. The Pharmacy Services segment operating profit included the favorable impact of a reversal of an accrual of $88 million in connection with a legal settlement. Corporate segment operating expenses decreased $92 million from the prior year primarily due to the $90 million legal charge in the prior year associated with a disputed 1999 legal settlement. For FY16, CVS' consolidated operating profit increased $884 million. Operating profit for the year had increased by $683 million in the Pharmacy Services segment and $151 million in the Retail/LTC segment. During Q4 2016, CVS opened 40 new retail stores and closed 25 retail stores. In addition, the Company relocated 16 retail stores. As of December 31, 2016, the Company operated 9,709 retail stores, including pharmacies in Target stores, in 49 states, the District of Columbia, Puerto Rico and Brazil. CVS intends to close approximately 70 retail stores during 2017 and expects to take a charge of approximately $225 million associated with the remaining lease obligations of such stores. The vast majority of the store closures are expected to occur in Q1 2017. In connection with such anticipated store closures, the Company recorded a $34 million asset impairment charge in Q4 2016. CVS expects to deliver GAAP diluted EPS of $5.02 to $5.18 and adjusted EPS of $5.77 to $5.93 for FY17. The Company expects to deliver GAAP diluted EPS of $0.82 to $0.88 and adjusted EPS of $1.07 to $1.13 in Q1 2017. The Company also confirmed its FY17 cash flow from operations guidance of $7.7 billion to $8.6 billion and free cash flow guidance of $6.0 billion to $6.4 billion. At the close of trading session on Tuesday, February 28, 2017, CVS Health's stock price slipped 1.02% to end the day at $80.58. A total volume of 7.27 million shares were exchanged during the session. The Company's share price has gained 9.46% in the past three months and 2.73% on YTD basis. The stock is trading at a PE ratio of 16.35 and has a dividend yield of 2.48%. Additionally, the stock currently has a market cap of $85.74 billion. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


LONDON, UK / ACCESSWIRE / March 1, 2017 / Active Wall St. announces its post-earnings coverage on CVS Health Corp. (NYSE: CVS). The Company released its financial results for the fourth quarter fiscal 2017 (Q4 FY17) and full year 2017 (FY17) on February 09, 2017. The Drugstore chain and pharmacy benefits manager's earnings outperformed market expectations. Register with us now for your free membership at: One of CVS Health's competitors within the Health Care Plans space, Magellan Health, Inc. (NASDAQ: MGLN), reported its earnings for Q4 ended on December 31, 2016, on Friday, February 24, 2017. AWS will be initiating a research report on Magellan Health in the coming days. Today, AWS is promoting its earnings coverage on CVS; touching on MGLN. Get our free coverage by signing up to: CVS announced that net revenues for the three months ended December 31, 2016, increased 11.7% to $46.0 billion, up from $41.1 billion in Q4 2015. The Company's revenue numbers came in below market estimates of $46.51 billion. For the year ended December 31, 2016, CVS' net revenues increased 15.8% to $177.5 billion compared to $153.3 billion for FY15. CVS' net income for Q4 2016 was $1.71 billion, or $1.59 per share, compared to net income of $1.50 billion, or $1.34 per share, during Q4 2015. The Company benefited from a lower effective income tax rate in the reported quarter of 38.0% versus 38.9% in the prior year's same period. CVS' adjusted earnings per share for Q4 2016 was $1.71 compared to $1.53 for Q4 2015, and surpassed analysts' consensus of $1.67 per share. The Company's GAAP diluted EPS for year ended December 31, 2016 was $4.91 compared to $4.62 in the prior year. Net income for the year ended December 31, 2016, was $5.3 billion, an increase of $80 million, or 1.5%. CVS generated approximately $1.5 billion of free cash during the quarter and $8.1 billion for the full year 2016, which was above the high-end of its guidance range. In FY16, CVS returned $6.3 billion to shareholders through dividends and share repurchases. During Q4 2016, the Company repurchased 6.1 million shares for $461 million, or $75.20 per share. In FY16, CVS repurchased 48 million shares for $4.5 billion, or $96.78 per share. CVS's revenues in the Pharmacy Services segment increased 17.9% to $31.3 billion in Q4 2016, primarily driven by growth in pharmacy network and specialty pharmacy claims. Pharmacy network claims processed during the reported period, increased 23.9% to 294.3 million, compared to 237.4 million in the prior year. The increase in pharmacy network claim volume was primarily due to an increase in net new business. CVS' Mail choice claims processed during Q4 2016, increased 4.7% to 23.2 million compared to 22.2 million in the prior year. CVS' revenues in the Retail/LTC segment increased 4.7% to $20.8 billion in Q4 2016, largely driven by the addition of the pharmacies of Target Corporation, which were acquired in December 2015. Pharmacy same store prescription volumes rose 2.0% on a 30-day equivalent basis. Same store sales decreased 0.7% versus the prior year, with pharmacy same store sales up 0.2% and front store same store sales down 2.9%. Front store same store sales were negatively impacted by softer customer traffic and efforts to rationalize promotional strategies, partially offset by an increase in basket size. Pharmacy same store sales were negatively impacted for Q4 2016 by approximately 380 basis points due to recent generic introductions. CVS reported that for Q4 2016, the generic dispensing rate increased approximately 170 basis points to 85.4% in its Pharmacy Services segment and increased approximately 120 basis points to 85.2% in the Company's Retail/LTC segment compared to the prior year. For Q4 2016, CVS' consolidated operating profit increased $266 million. Operating profit for the reported quarter increased $242 million in the Pharmacy Services segment and decreased $53 million in the Retail/LTC segment. The Pharmacy Services segment operating profit included the favorable impact of a reversal of an accrual of $88 million in connection with a legal settlement. Corporate segment operating expenses decreased $92 million from the prior year primarily due to the $90 million legal charge in the prior year associated with a disputed 1999 legal settlement. For FY16, CVS' consolidated operating profit increased $884 million. Operating profit for the year had increased by $683 million in the Pharmacy Services segment and $151 million in the Retail/LTC segment. During Q4 2016, CVS opened 40 new retail stores and closed 25 retail stores. In addition, the Company relocated 16 retail stores. As of December 31, 2016, the Company operated 9,709 retail stores, including pharmacies in Target stores, in 49 states, the District of Columbia, Puerto Rico and Brazil. CVS intends to close approximately 70 retail stores during 2017 and expects to take a charge of approximately $225 million associated with the remaining lease obligations of such stores. The vast majority of the store closures are expected to occur in Q1 2017. In connection with such anticipated store closures, the Company recorded a $34 million asset impairment charge in Q4 2016. CVS expects to deliver GAAP diluted EPS of $5.02 to $5.18 and adjusted EPS of $5.77 to $5.93 for FY17. The Company expects to deliver GAAP diluted EPS of $0.82 to $0.88 and adjusted EPS of $1.07 to $1.13 in Q1 2017. The Company also confirmed its FY17 cash flow from operations guidance of $7.7 billion to $8.6 billion and free cash flow guidance of $6.0 billion to $6.4 billion. At the close of trading session on Tuesday, February 28, 2017, CVS Health's stock price slipped 1.02% to end the day at $80.58. A total volume of 7.27 million shares were exchanged during the session. The Company's share price has gained 9.46% in the past three months and 2.73% on YTD basis. The stock is trading at a PE ratio of 16.35 and has a dividend yield of 2.48%. Additionally, the stock currently has a market cap of $85.74 billion. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


News Article | February 24, 2017
Site: www.prnewswire.com

PALM HARBOR, Fla., Feb. 23, 2017 /PRNewswire/ -- Synergy Pharmacy Services proudly announces its achievement of PCAB accreditation, a service of Accreditation Commission of Health Care (ACHC), thus joining an elite group of pharmacies nationwide with this distinction. The accreditation...


News Article | February 16, 2017
Site: www.businesswire.com

CREVE COEUR, Miss.--(BUSINESS WIRE)--Focus Script LLC, a leading independent specialized pharmacy claims management company and Arete Pharmacy Network, LLC, a national quality-focused Pharmacy Services Administrative Organization (PSAO), announced an exclusive partnership today. The partnership extends FocusScript’s compounding pharmacy accreditation, credentialing, and ongoing oversight to independent compounding pharmacies that are member pharmacies of Arete Pharmacy Network. The agreement means that the two companies will collaborate to ensure that Arete Pharmacy Network’s current and prospective compounding member pharmacies meet accreditation and credentialing standards incorporating compliance, quality, and performance standards necessary to compete on excellence in today’s managed care environment. Ensuring a pool of quality compounding pharmacies allows Pharmacy Benefit Managers (PBMs) and payors to grant contract access to the compounding pharmacies with confidence. Under the terms of the agreement, FocusScript will certify that pharmacies are accredited and credentialed through the industry leading UCAP program, which is administered through FocusScript’s exclusive partnership with the National Association of Boards of Pharmacy (NABP). Additionally, FocusScript will manage and process claims through its proprietary pre-processing system to deliver optimal pricing, broad analytics, and real-time oversight of Fraud, Waste and Abuse. Rob McMahan, CEO of Arete Pharmacy Network said, “The relationship between Arete Pharmacy Network and FocusScript will have immense benefits for both our member pharmacies and the payors we work with. Our collaboration with FocusScript—an expert in the compounding pharmacy field—reinforces our commitment to building a quality network by providing an additional avenue to serve compounding pharmacies.” Cynthia A. Meiners, President and CEO, Focus Script, LLC, stated, “FocusScript is dedicated to aligning the right people, shared values and technology needed to organize and oversee the delivery of quality standards, rational pricing and reasonable business practices to complex pharmacy markets. FocusScript provides the confidence to clients and providers that they can compete in these markets by offering optimum quality standards, pricing, and intelligent editing utilizing best practices with diligent oversight. We are excited to partner with the Arete Pharmacy Network in its commitment to these shared values.” Arete Pharmacy Network serves independent community pharmacies through a portfolio of expanded tools and services designed to help pharmacies deliver quality care to their communities. With a core focus on managed care contracting and service excellence, Arete Pharmacy Network supports the effective management of the financial, quality, and operational aspects of pharmacy business. For more information, visit www.areterx.com. Founded in 2014, the Company provides access to a network of certified pharmacies that provide specialized and compounded medications. Through an exclusive partnership with the National Association of Boards of Pharmacy (“NABP”), FocusScript’s network of compounding pharmacies is certified through the United Credentialing and Accreditation Program (“UCAP”). Using NABP’s Verified Pharmacy Program (“VPP”) as its foundation, the UCAP program includes a rigorous review of business and quality practices, attestation to a code of conduct, and compounding specific requirements. FocusScript is independent and unbiased, enabling us to work with all stakeholders and suppliers and to compete solely on excellence. For more information, visit www.focusscript.com.


BETHLEHEM, PA--(Marketwired - Feb 14, 2017) -  B. Braun Medical Inc., a leader in customized parenteral nutrition, will present its new parenteral nutrition program -- PN360 -- designed to improve neonatal, pediatric and adult patient outcomes -- at this year's American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Clinical Nutrition Week. "Our PN360 program unlocks a holistic, therapeutic approach to parenteral nutrition through our comprehensive offering of products, education, training and consultative services," said Rick Williamson, Vice President of Pharmaceutical Marketing at B. Braun. "PN360 is a team approach to help meet any facility's parenteral nutrition admixing needs," he said. "The program is more than individual in-house compounding, parenteral nutrition solutions and outsourced compounded products or services. It's an earnest collaboration with pharmacists, physicians, nurses and dietitians to tailor nutritional therapy for their most critical patients, as well as help reduce medical errors, infections and re-admissions." From Feb. 18-20 in the Marriott Orlando World Center in Orlando, Fla., B. Braun representatives at booth #201 also will showcase the company's new macro and micro APEX® compounding system for facilities that need in-house compounding capabilities. Through its browser-based TPN Manager software, health care providers can enter parenteral nutrition orders at the patient's bedside using an iPad or tablet with access to Trissel's Ca/P Safety Check Software™. These orders are EMR integrated and electronically transmitted to the APEX compounder, thereby helping to reduce manual programming errors, eliminate transcription errors, and expedite patient care. B. Braun also offers a wide selection of amino acid formulations, standard solutions, and related additives -- in containers that are not made with natural rubber latex, PVC or DEHP -- to help clinicians provide safe, appropriate nutritional support for patients' individualized needs. B. Braun was the first medical device manufacturer to remove harmful PVC and DEHP from many of its products. To learn more about B. Braun's commitment to protecting people and the environment while improving patient outcomes and reducing health care costs visit www.bbrauncares.com. Another integral part of PN360 is Central Admixture Pharmacy Services, Inc. (CAPS®), a B. Braun company -- the nation's largest network of outsourcing admixture pharmacies and a leader in customized parenteral nutrition. CAPS representatives will be at the booth to discuss the company's customized parenteral nutrition compounding services, including local, same-day delivery with safe, easy online ordering and a pharmacist to double-check on each order. About B. Braun B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the health care industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®. Globally, the B. Braun Group of Companies employs more than 56,000 employees in more than 60 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.

Loading Pharmacy Services collaborators
Loading Pharmacy Services collaborators